BioNTech's Gotistobart Nearly Doubles Survival in Phase 3, and Three Analysts Just Raised Their Targets

PRESERVE-003 showed gotistobart at 18.5 months median survival vs 10 for chemo; analysts raised targets as Sahin's pre-set sale drew notice.

Two things landed on BioNTech's desk this week, and they pull in opposite directions. One is a set of lung cancer data presented in Seoul that had sell-side analysts reaching for their calculators. The other is a regulatory filing showing CEO Ugur Sahin sold 49,000 shares across two sessions. The clinical result is the one that matters; the share sale is background noise, and here is why.

What PRESERVE-003 actually showed

The Phase 3 trial, dubbed PRESERVE-003, tested gotistobart — an anti-CTLA-4 antibody also known as BNT316/ONC-394 and developed with partner OncoC4 — in patients with advanced squamous lung cancer who had already been through at least one prior line of therapy. Median overall survival came in at 18.5 months, against 10 months for the docetaxel chemotherapy comparator. That is close to a doubling, a magnitude that rarely shows up in oncology readouts.

Response rates tell a similar story: 20% for gotistobart versus 4.8% for chemo, with tolerability described as comparable. The asset already carries FDA fast-track and orphan-drug designations.

Earlier Phase 1 data back the picture. Death risk ran 54% lower than with docetaxel, and median survival in the treatment arm was never reached, while the control group sat at 9.95 months. At the twelve-month mark, 55.6% of patients on the drug were still alive, compared with 23.8% on docetaxel.

None of this is a guarantee of commercial success — the road from Phase 3 to approval is long. But it shifts the odds meaningfully in BioNTech's favor, and investors who have spent months sidestepping the stock over choppy pipeline headlines should not skim past it.

A second readout, and a wave of target hikes

BioNTech also used the WCLC stage to present combination data for pumitamig plus elfetabart in first-line small cell lung cancer. Berenberg pegged the response rate at 92% in first-line treatment, 76% in second-line, and still 52% among heavily pretreated patients. UBS analyst David Dai noted no dose-limiting toxicities, with a discontinuation rate of just 3.9%.

The Street responded in unison on Wednesday. Dai kept his Buy rating and a $135 target, pointing to an interim readout expected in 2026 and a possible regulatory filing in 2027. Jefferies' Akash Tewari reiterated Buy with a $138 target. Berenberg's Harry Gillis went furthest, lifting his target from $132 to $140. Berenberg sizes the peak sales opportunity for pumitamig at $5 billion on a 50% probability of success, and elfetabart at $3 billion. The discontinued iNeST colorectal cancer vaccine candidate fades further into the background of the investment case.

The insider sale, put in proportion

Sahin offloaded 49,000 shares on September 15 and 16 at prices around $96, executed under a Rule 10b5-1 plan put in place back in June. That distinction matters: the plan was locked in long before this week's data, which rules out a panicked exit. After the transactions he still holds 553,209 shares directly, plus more than 39.2 million indirectly through Medine GmbH. Someone trimming a sliver of their stake via a pre-set schedule is not sending a warning signal. The timing coincidence with the Seoul news will get overread on the trading floor, but it deserves no more weight than that.

The tape is not joining the party

In Frankfurt the stock closed Wednesday at EUR 83.60, down 0.2% from the previous session, hovering near its 50-day moving average of EUR 84.21. That leaves it roughly 21% below the 52-week high of EUR 105.80 set in January, and 22% above the March low of EUR 68.35. Hardly euphoric, hardly despairing — a market waiting for confirmation. New York traded more strongly, a contrast with the muted German reaction.

Thirty-day volatility of 72% shows how twitchy the tape is to every fresh headline, which for a company with an oncology pipeline of this scale reads as a structural feature rather than a red flag. Fair-value estimates from the analyst community imply meaningful upside from current US levels, with discounts of around a fifth against price targets. Such models warrant caution, but they reinforce the case that the market has not fully priced the recent clinical progress.

Competition is not standing still. Johnson & Johnson used the same conference to present new survival data for its RYBREVANT regimen in EGFR-mutated lung cancer, and OncoC4 separately picked up FDA fast-track status for another candidate, cesalatamig.

For BioNTech shareholders, the message out of Seoul is unambiguous: after a stretch of muted expectations, the oncology pipeline is once again producing hard clinical arguments — and three separate analyst houses are staking their recommendations on them. The open question is whether the Phase 3 data convert into a regulatory green light. Until then, the stock remains a tug-of-war between scientific progress and investor patience.